This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The analysis compared new guidelines of type 2 diabetes (according to therapeutic goals defined by Diabetes Poland) with the conventional clinical practice for this patient population.
The guideline goals included blood pressure control and appropriate levels of total, low-density and high-density cholesterol and triglycerides.
Location/setting
Poland. Primary care.
Methods

Analytical approach:
The analysis was based on the previously published CORE model that simulated disease progression over a patient's lifetime. The authors stated that the study took the perspective of public payer.
Effectiveness data:
A selective approach was used to identify data sources. Most evidence on baseline characteristics of the patient population were taken from a study of the Polish population supplemented with data from the United Kingdom Prospective Diabetes Study (UKDPS). Other data were already incorporated in the CORE model. The efficacy of treatment was the main endpoint and was estimated by assessing disease progression (change over time for control of glycaemia, blood pressure and lipid metabolism) in the patient population as observed in the Polish database for the conventional care and the achievement of therapeutic goals defined in the guidelines for the intense care strategy.
Monetary benefit and utility valuations:
Sources of utility valuations were not explicitly stated but may have already been incorporated in the decision model.
Measure of benefit:
Quality-adjusted life-years (QALYs) were used as the summary benefit measure and were discounted at an annual rate of 3.5%. The economic analysis included two main cost categories: costs associated with the interventions (mainly pharmacotherapy) and costs associated with the treatment of complications. Drug costs were based on official price lists. Patterns of resource consumption were mostly estimated using expert opinion and taken from a manufacturer. Costs of complications were based on prices of medical services established by the National Health Fund. Costs were in Euros (€). A 5% annual discount rate was applied. The price year was 2011.
Cost data:
Analysis of uncertainty:
Deterministic sensitivity analyses were carried out to investigate the impact on the model outcomes of variations in baseline patient characteristics and proportions of patients on hypotensive and hypolipaemic agents.
Results
Deterministic sensitivity analyses were carried out to investigate the impact of variations in baseline patient characteristics and proportions of patients on hypotensive and hypolipaemic agents on the model outcomes.
QALYs were 8.1 with usual care and 8.4 with intense treatment.
Costs of treating complications were €5,950 with usual care and €5,550 with intense treatment.
If intense treatment cost €250 per patient per year more than usual care, the incremental cost per QALY gained with intense treatment would be €7,500.
Using a threshold value of €25,511 corresponding to three times the gross domestic product (GDP) per capita, intense treatment would be cost-effective up to a treatment cost of €750 per year relative to usual care.
The sensitivity analysis showed that better health conditions of patients at baseline (especially in terms of blood pressure and high-density lipoprotein cholesterol) improved the cost-effectiveness of intensive treatment. Variations in use of hypotensive and hypolipaemic agents did not alter the conclusions of the analysis.
